Novel chemokine related LncRNA signature correlates with the … – BMC Gastroenterology

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394424.

Article PubMed Google Scholar

Arnold M, Soerjomataram I, Ferlay J, Forman D. Global incidence of oesophageal cancer by histological subtype in 2012. Gut. 2015;64(3):3817.

Article PubMed Google Scholar

Hersznyi L, Tulassay Z. Epidemiology of gastrointestinal and liver tumors. Eur Rev Med Pharmacol Sci. 2010;14(4):24958.

PubMed Google Scholar

Wang WL, Chang WL, Yang HB, Wang YC, Chang IW, Lee CT, Chang CY, Lin JT, Sheu BS. Low disabled-2 expression promotes tumor progression and determines poor survival and high recurrence of esophageal squamous cell carcinoma. Oncotarget. 2016;7(44):7116981.

Article PubMed PubMed Central Google Scholar

Aquino JL, Said MM, Pereira DA, Cecchino GN, Leandro-Merhi VA. Complications of the rescue esophagectomy in advanced esophageal cancer. Arq Bras Cir Dig. 2013;26(3):1738 ABCD = Brazilian archives of digestive surgery.

Article PubMed Google Scholar

Zhang J, Ling X, Fang C, Ma J. Identification and validation of an eight-lncRNA signature that predicts prognosis in patients with esophageal squamous cell carcinoma. Cell Mol Biol Lett. 2022;27(1):39.

Article CAS PubMed PubMed Central Google Scholar

Zheng ZJ, Li YS, Zhu JD, Zou HY, Fang WK, Cui YY, Xie JJ. Construction of the Six-lncRNA prognosis signature as a novel biomarker in esophageal squamous cell carcinoma. Front Genet. 2022;13: 839589.

Article CAS PubMed PubMed Central Google Scholar

Chi Y, Wang D, Wang J, Yu W, Yang J. Long Non-Coding RNA in the pathogenesis of cancers. Cells. 2019;8(9):1015.

Article CAS PubMed PubMed Central Google Scholar

Fang P, Chen H, Ma Z, Han C, Yin W, Wang S, Zhu H, Xia W, Wang J, Xu L, et al. lncRNA LINC00525 suppresses p21 expression via mRNA decay and triplex-mediated changes in chromatin structure in lung adenocarcinoma. Cancer Commun (London, England). 2021;41(7):596614.

Article Google Scholar

Sheykhhasan M, Ahmadyousefi Y, Seyedebrahimi R, Tanzadehpanah H, Manoochehri H, Dama P, Hosseini NF, Akbari M, Eslami Farsani M. DLX6-AS1: a putative lncRNA candidate in multiple human cancers. Expert Rev Mol Med. 2021;23: e17.

Article CAS PubMed Google Scholar

Bhan A, Soleimani M, Mandal SS. Long Noncoding RNA and Cancer: A New Paradigm. Can Res. 2017;77(15):396581.

Article CAS Google Scholar

Zhu J, Zhao Y, Wu G, Zhang X, Chen Q, Yang B, Guo X, Ji S, Gu K. Ferroptosis-related lncRNA signature correlates with the prognosis, tumor microenvironment, and therapeutic sensitivity of esophageal squamous cell carcinoma. Oxid Med Cell Longev. 2022;2022:7465880.

Article PubMed PubMed Central Google Scholar

Zhao F, Li Y, Dong Z, Zhang D, Guo P, Li Z, Li S. Identification of a risk signature based on lactic acid metabolism-related lncRNAs in patients with esophageal squamous cell carcinoma. Front Cell Dev Biol. 2022;10:845293.

Article PubMed PubMed Central Google Scholar

Zhao F, Dong Z, Li Y, Liu S, Guo P, Zhang D, Li S. Comprehensive analysis of molecular clusters and prognostic signature based on m7G-related lncRNAs in esophageal squamous cell carcinoma. Front Oncol. 2022;12: 893186.

Article PubMed PubMed Central Google Scholar

Shi X, Liu X, Pan S, Ke Y, Li Y, Guo W, Wang Y, Ruan Q, Zhang X, Ma H. A novel autophagy-related long non-coding RNA signature to predict prognosis and therapeutic response in esophageal squamous cell carcinoma. Int J Gen Med. 2021;14:832539.

Article CAS PubMed PubMed Central Google Scholar

Zhu T, Ma Z, Wang H, Wei D, Wang B, Zhang C, Fu L, Li Z, Yu G. Immune-related long non-coding RNA signature and clinical nomogram to evaluate survival of patients suffering esophageal squamous cell carcinoma. Front Cell Dev Biol. 2021;9:641960.

Article PubMed PubMed Central Google Scholar

Mantovani A, Savino B, Locati M, Zammataro L, Allavena P, Bonecchi R. The chemokine system in cancer biology and therapy. Cytokine Growth Factor Rev. 2010;21(1):2739.

Article CAS PubMed Google Scholar

Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol. 2017;17(9):55972.

Article CAS PubMed PubMed Central Google Scholar

Dangaj D, Bruand M, Grimm AJ, Ronet C, Barras D, Duttagupta PA, Lanitis E, Duraiswamy J, Tanyi JL, Benencia F, et al. Cooperation between constitutive and inducible chemokines enables T cell engraftment and immune attack in solid tumors. Cancer Cell. 2019;35(6):885-900.e810.

Article CAS PubMed PubMed Central Google Scholar

Lim SJ. CCL24 signaling in the tumor microenvironment. Adv Exp Med Biol. 2021;1302:918.

Article PubMed Google Scholar

Harrow J, Frankish A, Gonzalez JM, Tapanari E, Diekhans M, Kokocinski F, Aken BL, Barrell D, Zadissa A, Searle S, et al. GENCODE: the reference human genome annotation for the ENCODE project. Genome Res. 2012;22(9):176074.

Article CAS PubMed PubMed Central Google Scholar

White NM, Cabanski CR, Silva-Fisher JM, Dang HX, Govindan R, Maher CA. Transcriptome sequencing reveals altered long intergenic non-coding RNAs in lung cancer. Genome Biol. 2014;15(8):429.

Article PubMed PubMed Central Google Scholar

Guo JC, Wu Y, Chen Y, Pan F, Wu ZY, Zhang JS, Wu JY, Xu XE, Zhao JM, Li EM, et al. Protein-coding genes combined with long noncoding RNA as a novel transcriptome molecular staging model to predict the survival of patients with esophageal squamous cell carcinoma. Cancer Commun (London, England). 2018;38(1):4.

Article Google Scholar

Zlotnik A, Yoshie O. The chemokine superfamily revisited. Immunity. 2012;36(5):70516.

Article CAS PubMed PubMed Central Google Scholar

Griffith JW, Sokol CL, Luster AD. Chemokines and chemokine receptors: positioning cells for host defense and immunity. Annu Rev Immunol. 2014;32:659702.

Article CAS PubMed Google Scholar

Sokol CL, Luster AD. The chemokine system in innate immunity. Cold Spring Harb Perspect Biol. 2015;7(5):a016303.

Article PubMed PubMed Central Google Scholar

Tiberio L, Del Prete A, Schioppa T, Sozio F, Bosisio D, Sozzani S. Chemokine and chemotactic signals in dendritic cell migration. Cell Mol Immunol. 2018;15(4):34652.

Article CAS PubMed PubMed Central Google Scholar

Wang X, Zhao Y, Strohmer DF, Yang W, Xia Z, Yu C. The prognostic value of MicroRNAs associated with fatty acid metabolism in head and neck squamous cell carcinoma. Front Genet. 2022;13: 983672.

Article CAS PubMed PubMed Central Google Scholar

Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28(1):2730.

Article CAS PubMed PubMed Central Google Scholar

Kanehisa M. Toward understanding the origin and evolution of cellular organisms. Protein Sci. 2019;28(11):194751.

Article CAS PubMed PubMed Central Google Scholar

Kanehisa M, Furumichi M, Sato Y, Ishiguro-Watanabe M, Tanabe M. KEGG: integrating viruses and cellular organisms. Nucleic Acids Res. 2021;49(D1):D545-d551.

Article CAS PubMed Google Scholar

Chi H, Xie X, Yan Y, Peng G, Strohmer DF, Lai G, Zhao S, Xia Z, Tian G. Natural killer cell-related prognosis signature characterizes immune landscape and predicts prognosis of HNSCC. Front Immunol. 2022;13:1018685.

Article CAS PubMed PubMed Central Google Scholar

Chi H, Jiang P, Xu K, Zhao Y, Song B, Peng G, He B, Liu X, Xia Z, Tian G. A novel anoikis-related gene signature predicts prognosis in patients with head and neck squamous cell carcinoma and reveals immune infiltration. Front Genet. 2022;13: 984273.

Article CAS PubMed PubMed Central Google Scholar

Korbecki J, Kupnicka P, Chlubek M, Gorcy J, Gutowska I, Baranowska-Bosiacka I. CXCR2 receptor: regulation of expression, signal transduction, and involvement in Cancer. Int J Mol Sci. 2022;23(4):2168.

Article CAS PubMed PubMed Central Google Scholar

Bill CA, Allen CM, Vines CM. C-C Chemokine receptor 7 in cancer. Cells. 2022;11(4):656.

Article CAS PubMed PubMed Central Google Scholar

Gong X, Chi H, Strohmer DF, Teichmann AT, Xia Z, Wang Q. Exosomes: a potential tool for immunotherapy of ovarian cancer. Front Immunol. 2023;13:1089410.

Article PubMed PubMed Central Google Scholar

Yura M, Fukuda K, Matsuda S, Irino T, Nakamura R, Kawakubo H, Takeuchi H, Kitagawa Y. Effects of let-7a microRNA and C-C chemokine receptor type 7 expression on cellular function and prognosis in esophageal squamous cell carcinoma. BMC Cancer. 2022;22(1):1064.

Article CAS PubMed PubMed Central Google Scholar

Guo J, Tong CY, Shi JG, Li XJ. C-X-C motif chemokine ligand 12 (CXCL12)/C-X-C motif chemokine receptor 7(CXCR7) regulates epithelial-mesenchymal transition process and promotes the metastasis of esophageal cancer by activating signal transducer and activator of transcription 3 (STAT3) pathway. Bioengineered. 2022;13(3):742538.

Article CAS PubMed PubMed Central Google Scholar

Zhong YB, Shan AJ, Lv W, Wang J, Xu JZ. Long non-coding RNA LINC00675 inhibits tumorigenesis and EMT via repressing Wnt/-catenin signaling in esophageal squamous cell carcinoma. Eur Rev Med Pharmacol Sci. 2018;22(23):828897.

PubMed Google Scholar

Zhu Z, Wang H, Pang Y, Hu H, Zhang H, Wang W. Exosomal long non-coding RNA UCA1 functions as growth inhibitor in esophageal cancer. Aging. 2020;12(20):8581.

Article Google Scholar

Wang X, Gao Z, Liao J, Shang M, Li X, Yin L, Pu Y, Liu R. lncRNA UCA1 inhibits esophageal squamous-cell carcinoma growth by regulating the Wnt signaling pathway. J Toxicol Environ Health Part A. 2016;79(910):40718.

Article CAS Google Scholar

Wang X, Sun M, Gao Z, Yin L, Pu Y, Zhu Y, Wang X, Liu R. N-nitrosamines-mediated downregulation of lncRNA-UCA1 induces carcinogenesis of esophageal squamous by regulating the alternative splicing of FGFR2. Sci Total Environ. 2023;855: 158918.

Article CAS PubMed Google Scholar

Gautam SK, Basu S, Aithal A, Dwivedi NV, Gulati M, Jain M. Regulation of pancreatic cancer therapy resistance by chemokines. Semin Cancer Biol. 2022;86(Pt 2):6980.

Article CAS PubMed Google Scholar

Bhat AA, Nisar S, Maacha S, Carneiro-Lobo TC, Akhtar S, Siveen KS, Wani NA, Rizwan A, Bagga P, Singh M, et al. Cytokine-chemokine network driven metastasis in esophageal cancer; promising avenue for targeted therapy. Mol Cancer. 2021;20(1):2.

Article PubMed PubMed Central Google Scholar

Fujikawa M, Koma YI, Hosono M, Urakawa N, Tanigawa K, Shimizu M, Kodama T, Sakamoto H, Nishio M, Shigeoka M, et al. Chemokine (C-C Motif) Ligand 1 derived from tumor-associated macrophages contributes to esophageal squamous cell carcinoma progression via CCR8-mediated Akt/Proline-rich Akt substrate of 40 kDa/Mammalian target of rapamycin pathway. Am J Pathol. 2021;191(4):686703.

Article CAS PubMed Google Scholar

Zhao Y, Wei K, Chi H, Xia Z, Li X. IL-7: a promising adjuvant ensuring effective T cell responses and memory in combination with cancer vaccines? Front Immunol. 2022;13:1022808.

Article CAS PubMed PubMed Central Google Scholar

Ugel S, Can S, De Sanctis F, Bronte V. Monocytes in the tumor microenvironment. Annu Rev Pathol. 2021;16:93122.

Article CAS PubMed Google Scholar

Cassetta L, Pollard JW. Targeting macrophages: therapeutic approaches in cancer. Nat Rev Drug Discovery. 2018;17(12):887904.

Article CAS PubMed Google Scholar

Wu Z, Zhang X, Chen D, Li Z, Wu X, Wang J, Deng Y. N6-Methyladenosine-related lncRNAs are potential remodeling indicators in the tumor microenvironment and prognostic markers in osteosarcoma. Front Immunol. 2021;12: 806189.

Article CAS PubMed Google Scholar

Zhou R, Liang J, Tian H, Chen Q, Yang C, Liu C. Development of a Ferroptosis-related lncRNA signature to predict the prognosis and immune landscape of bladder cancer. Dis Markers. 2021;2021:1031906.

Article PubMed PubMed Central Google Scholar

Read more:
Novel chemokine related LncRNA signature correlates with the ... - BMC Gastroenterology

Long- and very long-chain ceramides are predictors of acute kidney … – Cardiovascular Diabetology

Marenzi G, Cosentino N, Bartorelli AL. Acute kidney injury in patients with acute coronary syndromes. Heart. 2015;101(22):177885.

Article CAS PubMed Google Scholar

Marenzi G, Cabiati A, Bertoli SV, Assanelli E, Marana I, De Metrio M, Rubino M, Moltrasio M, Grazi M, Campodonico J, et al. Incidence and relevance of acute kidney injury in patients hospitalized with acute coronary syndromes. Am J Cardiol. 2013;111(6):81622.

Article PubMed Google Scholar

Goldberg A, Hammerman H, Petcherski S, Zdorovyak A, Yalonetsky S, Kapeliovich M, Agmon Y, Markiewicz W, Aronson D. Inhospital and 1-year mortality of patients who develop worsening renal function following acute ST-elevation myocardial infarction. Am Heart J. 2005;150(2):3307.

Article PubMed Google Scholar

Kaltsas E, Chalikias G, Tziakas D. The incidence and the prognostic impact of acute kidney injury in acute myocardial infarction patients: current preventive strategies. Cardiovasc Drugs Ther. 2018;32(1):8198.

Article PubMed Google Scholar

Marenzi G, Assanelli E, Campodonico J, De Metrio M, Lauri G, Marana I, Moltrasio M, Rubino M, Veglia F, Montorsi P, et al. Acute kidney injury in ST-segment elevation acute myocardial infarction complicated by cardiogenic shock at admission. Crit Care Med. 2010;38(2):43844.

Article PubMed Google Scholar

Gault CR, Obeid LM, Hannun YA. An overview of sphingolipid metabolism: from synthesis to breakdown. Adv Exp Med Biol. 2010;688:123.

Article CAS PubMed PubMed Central Google Scholar

Anroedh S, Hilvo M, Akkerhuis KM, Kauhanen D, Koistinen K, Oemrawsingh R, Serruys P, van Geuns RJ, Boersma E, Laaksonen R, et al. Plasma concentrations of molecular lipid species predict long-term clinical outcome in coronary artery disease patients. J Lipid Res. 2018;59(9):172937.

Article CAS PubMed PubMed Central Google Scholar

Cheng JM, Suoniemi M, Kardys I, Vihervaara T, de Boer SP, Akkerhuis KM, Sysi-Aho M, Ekroos K, Garcia-Garcia HM, Oemrawsingh RM, et al. Plasma concentrations of molecular lipid species in relation to coronary plaque characteristics and cardiovascular outcome: results of the ATHEROREMO-IVUS study. Atherosclerosis. 2015;243(2):5606.

Article CAS PubMed Google Scholar

Laaksonen R, Ekroos K, Sysi-Aho M, Hilvo M, Vihervaara T, Kauhanen D, Suoniemi M, Hurme R, Mrz W, Scharnagl H, et al. Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol. Eur Heart J. 2016;37(25):196776.

Article CAS PubMed PubMed Central Google Scholar

Tu C, Xie L, Wang Z, Zhang L, Wu H, Ni W, Li C, Li L, Zeng Y. Association between ceramides and coronary artery stenosis in patients with coronary artery disease. Lipids Health Dis. 2020;19(1):151.

Article CAS PubMed PubMed Central Google Scholar

Peterson LR, Xanthakis V, Duncan MS, Gross S, Friedrich N, Volzke H, Felix SB, Jiang H, Sidhu R, Nauck M, et al. Ceramide remodeling and risk of cardiovascular events and mortality. J Am Heart Assoc. 2018. https://doi.org/10.1161/JAHA.117.007931.

Article PubMed PubMed Central Google Scholar

Tarasov K, Ekroos K, Suoniemi M, Kauhanen D, Sylvnne T, Hurme R, Gouni-Berthold I, Berthold HK, Kleber ME, Laaksonen R, et al. Molecular lipids identify cardiovascular risk and are efficiently lowered by simvastatin and PCSK9 deficiency. J Clin Endocrinol Metab. 2014;99(1):E45-52.

Article PubMed Google Scholar

Nwabuo CC, Duncan M, Xanthakis V, Peterson LR, Mitchell GF, McManus D, Cheng S, Vasan RS. Association of circulating ceramides with cardiac structure and function in the community: the framingham heart study. J Am Heart Assoc. 2019;8(19):e013050.

Article PubMed PubMed Central Google Scholar

Li PL, Zhang Y. Cross talk between ceramide and redox signaling: implications for endothelial dysfunction and renal disease. Handb Exp Pharmacol. 2013;216:17197.

Article CAS Google Scholar

Basnakian AG, Ueda N, Hong X, Galitovsky VE, Yin X, Shah SV. Ceramide synthase is essential for endonuclease-mediated death of renal tubular epithelial cells induced by hypoxia-reoxygenation. Am J Physiol Renal Physiol. 2005;288(2):F308-314.

Article CAS PubMed Google Scholar

Ueda N. Ceramide-induced apoptosis in renal tubular cells: a role of mitochondria and sphingosine-1-phoshate. Int J Mol Sci. 2015;16(3):5076124.

Article CAS PubMed PubMed Central Google Scholar

Ostermann M, Liu K. Pathophysiology of AKI. Best Pract Res Clin Anaesthesiol. 2017;31(3):30514.

Article PubMed Google Scholar

Raichur S, Brunner B, Bielohuby M, Hansen G, Pfenninger A, Wang B, Bruning JC, Larsen PJ, Tennagels N. The role of C16:0 ceramide in the development of obesity and type 2 diabetes: CerS6 inhibition as a novel therapeutic approach. Mol Metab. 2019;21:3650.

Article CAS PubMed PubMed Central Google Scholar

Turpin SM, Nicholls HT, Willmes DM, Mourier A, Brodesser S, Wunderlich CM, Mauer J, Xu E, Hammerschmidt P, Bronneke HS, et al. Obesity-induced CerS6-dependent C16:0 ceramide production promotes weight gain and glucose intolerance. Cell Metab. 2014;20(4):67886.

Article CAS PubMed Google Scholar

Fekry B, Jeffries KA, Esmaeilniakooshkghazi A, Ogretmen B, Krupenko SA, Krupenko NI. CerS6 is a novel transcriptional target of p53 protein activated by non-genotoxic stress. J Biol Chem. 2016;291(32):1658696.

Article CAS PubMed PubMed Central Google Scholar

Yacoub A, Hamed HA, Allegood J, Mitchell C, Spiegel S, Lesniak MS, Ogretmen B, Dash R, Sarkar D, Broaddus WC, et al. PERK-dependent regulation of ceramide synthase 6 and thioredoxin play a key role in mda-7/IL-24-induced killing of primary human glioblastoma multiforme cells. Cancer Res. 2010;70(3):11209.

Article CAS PubMed PubMed Central Google Scholar

Eberle M, Ebel P, Wegner MS, Mannich J, Tafferner N, Ferreiros N, Birod K, Schreiber Y, Krishnamoorthy G, Willecke K, et al. Regulation of ceramide synthase 6 in a spontaneous experimental autoimmune encephalomyelitis model is sex dependent. Biochem Pharmacol. 2014;92(2):32635.

Article CAS PubMed Google Scholar

Bai X, He T, Liu M, Li L, Chen J, Cao M, Liu Y, Yang C, Jia W, Tao K, et al. Integrative analysis of MicroRNAs and mRNAs in LPS-induced macrophage inflammation based on adipose tissue stem cell therapy. Inflammation. 2021;44(1):40720.

Article CAS PubMed Google Scholar

Hernandez-Corbacho MJ, Canals D, Adada MM, Liu M, Senkal CE, Yi JK, Mao C, Luberto C, Hannun YA, Obeid LM. Tumor Necrosis Factor-alpha (TNFalpha)-induced ceramide generation via ceramide synthases regulates loss of Focal Adhesion Kinase (FAK) and programmed cell death. J Biol Chem. 2015;290(42):2535673.

Article CAS PubMed PubMed Central Google Scholar

Kim YR, Lee EJ, Shin KO, Kim MH, Pewzner-Jung Y, Lee YM, Park JW, Futerman AH, Park WJ. Hepatic triglyceride accumulation via endoplasmic reticulum stress-induced SREBP-1 activation is regulated by ceramide synthases. Exp Mol Med. 2019;51(11):116.

PubMed PubMed Central Google Scholar

Stiban J, Perera M. Very long chain ceramides interfere with C16-ceramide-induced channel formation: a plausible mechanism for regulating the initiation of intrinsic apoptosis. Biochim Biophys Acta. 2015;1848(2):5617.

Article CAS PubMed Google Scholar

Nicholson RJ, Pezzolesi MG, Summers SA. Rotten to the cortex: ceramide-mediated lipotoxicity in diabetic kidney disease. Front Endocrinol (Lausanne). 2020;11:622692.

Article PubMed Google Scholar

Mantovani A, Lunardi G, Bonapace S, Dugo C, Altomari A, Molon G, Conti A, Bovo C, Laaksonen R, Byrne CD, et al. Association between increased plasma ceramides and chronic kidney disease in patients with and without ischemic heart disease. Diabetes Metab. 2021;47(1):101152.

Article CAS PubMed Google Scholar

Mitsnefes M, Scherer PE, Friedman LA, Gordillo R, Furth S, Warady BA. Ceramides and cardiac function in children with chronic kidney disease. Pediatric Nephrol (Berlin, Germany). 2014;29(3):41522.

Article Google Scholar

Ichi I, Kamikawa C, Nakagawa T, Kobayashi K, Kataoka R, Nagata E, Kitamura Y, Nakazaki C, Matsura T, Kojo S. Neutral sphingomyelinase-induced ceramide accumulation by oxidative stress during carbon tetrachloride intoxication. Toxicology. 2009;261(12):3340.

Article CAS PubMed Google Scholar

Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, Jaffe AS, Jneid H, Kelly RF, Kontos MC, et al. 2014 AHA/ACC guideline for the management of patients with Non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2014;64(24):e139228.

Article PubMed Google Scholar

OGara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;61(4):e78140.

Article PubMed Google Scholar

Granger CB, Goldberg RJ, Dabbous O, Pieper KS, Eagle KA, Cannon CP, Van De Werf F, Avezum A, Goodman SG, Flather MD, et al. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med. 2003;163(19):234553.

Article PubMed Google Scholar

Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol. 1983;51(3):606.

Article CAS PubMed Google Scholar

Jia Y, Gao Y, Li D, Cao Y, Cheng Y, Li F, Xiao L, Jiang Y, Wan Z, Zeng Z, et al. Geriatric nutritional risk index score predicts clinical outcome in patients with acute ST-segment elevation myocardial infarction. J Cardiovasc Nurs. 2020;35(6):E44-e52.

Article PubMed Google Scholar

Jia Y, Li H, Li D, Li F, Li Q, Jiang Y, Gao Y, Wan Z, Cao Y, Zeng Z, et al. Prognostic value of Braden scale in patients with acute myocardial infarction: from the retrospective multicenter study for early evaluation of acute chest pain. J Cardiovasc Nurs. 2020;35(6):E53-e61.

Article PubMed Google Scholar

Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, Mintz GS, Lansky AJ, Moses JW, Stone GW, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004;44(7):13939.

PubMed Google Scholar

Section 2: AKI Definition. Kidney international supplements 2012;2(1):1936. https://doi.org/10.1038/kisup.2011.32

Sarafian MH, Gaudin M, Lewis MR, Martin FP, Holmes E, Nicholson JK, Dumas ME. Objective set of criteria for optimization of sample preparation procedures for ultra-high throughput untargeted blood plasma lipid profiling by ultra performance liquid chromatography-mass spectrometry. Anal Chem. 2014;86(12):576674.

Article CAS PubMed Google Scholar

Huang Q, Hao S, Yao X, You J, Li X, Lai D, Han C, Schilling J, Hwa KY, Thyparambil S, et al. High-throughput quantitation of serological ceramides/dihydroceramides by LC/MS/MS: pregnancy baseline biomarkers and potential metabolic messengers. J Pharm Biomed Anal. 2021;192:113639.

Article CAS PubMed Google Scholar

Pickering JW, Blunt IRH, Than MP. Acute kidney injury and mortality prognosis in acute coronary syndrome patients: a meta-analysis. Nephrology (Carlton). 2018;23(3):23746.

Article PubMed Google Scholar

Yu J, Li D, Jia Y, Li F, Jiang Y, Zhang Q, Gao Y, Liao X, Zeng R, Wan Z. Nutritional risk screening 2002 was associated with acute kidney injury and mortality in patients with acute coronary syndrome: Insight from the REACP study. Nutr Metab Cardiovasc Dis. 2021;31(4):11218.

Article PubMed Google Scholar

Gencer B, Morrow DA, Braunwald E, Goodrich EL, Hilvo M, Kauhanen D, Sabatine MS, Laaksonen R, ODonoghue ML. Plasma ceramide and phospholipid-based risk score and the risk of cardiovascular death in patients after acute coronary syndrome. Eur J Prev Cardiol. 2020. https://doi.org/10.1093/eurjpc/zwaa143.

Article PubMed Google Scholar

Yao K, Wang Y, Xu D, Liu X, Shen C, Hu W, Wang Z, Wu R, Tang X, Sun A, et al. Effect of combined testing of ceramides with high-sensitive troponin T on the detection of acute coronary syndrome in patients with chest pain in China: a prospective observational study. BMJ Open. 2019;9(7):e028211.

Article PubMed PubMed Central Google Scholar

Abells-Sequeiros RA, Raposeiras-Roubn S, Abu-Assi E, Gonzlez-Salvado V, Iglesias-lvarez D, Redondo-Diguez A, Gonzlez-Ferreiro R, Ocaranza-Snchez R, Pea-Gil C, Garca-Acua JM, et al. Mehran contrast nephropathy risk score: Is it still useful 10 years later? J Cardiol. 2016;67(3):2627.

Article PubMed Google Scholar

Koowattanatianchai S, Chantadansuwan T, Kaladee A, Phinyo P, Patumanond J. Practical risk stratification score for prediction of contrast-induced nephropathy after primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction. Cardiol Res. 2019;10(6):3507.

Article PubMed PubMed Central Google Scholar

Rodriguez F, Bonacasa B, Fenoy FJ, Salom MG. Reactive oxygen and nitrogen species in the renal ischemia/reperfusion injury. Curr Pharm Des. 2013;19(15):277694.

Article CAS PubMed Google Scholar

Ueda N, Camargo SMR, Hong X, Basnakian AG, Walker PD, Shah SV. Role of ceramide synthase in oxidant injury to renal tubular epithelial cells. J Am Soc Nephrol. 2001;12(11):238491.

Article CAS PubMed Google Scholar

Kalhorn T, Zager RA. Renal cortical ceramide patterns during ischemic and toxic injury: assessments by HPLC-mass spectrometry. Am J Physiol. 1999;277(5):F723-733.

CAS PubMed Google Scholar

Bergman BC, Brozinick JT, Strauss A, Bacon S, Kerege A, Bui HH, Sanders P, Siddall P, Kuo MS, Perreault L. Serum sphingolipids: relationships to insulin sensitivity and changes with exercise in humans. Am J Physiol Endocrinol Metab. 2015;309(4):E398-408.

Article CAS PubMed PubMed Central Google Scholar

Couto SMF, Machado DI, Conde C, Silva VC, Souza AA, Peres KB, Brandi BA, Vattimo MFF. Physical training is a potential modifier of risk for contrast-induced acute kidney injury in diabetes mellitus. Biomed Res Int. 2020;2020:1830934.

More here:
Long- and very long-chain ceramides are predictors of acute kidney ... - Cardiovascular Diabetology

New strategy positions B.C. as a global hub for life sciences | BC … – BC Gov News

Selina Robinson, Minister of Post-Secondary Education and Future Skills

Our life sciences sector is vital to creating a future of prosperity and innovation. Our Province is focused on preparing people for the jobs of tomorrow through our Future Ready plan, which will make education more accessible, affordable and relevant so we can build a stronger B.C. together.

Wendy Hurlburt, president and chief executive officer, Life Sciences BC

Building on the momentum of our life sciences thriving sector, this first-ever provincial life sciences strategy sets B.C. up to be a global leader in life sciences and will advance the health of British Columbians through the discovery and development of innovative products, solutions and services while diversifying and growing our economy by creating high-paying jobs.

Dr. Allen Eaves, president and chief executive officer, StemcellTechnologies

As Canadas largest biotechnology company, StemcellTechnologies is experiencing tremendous growth along with many other biotechs in B.C. All of us will require more homegrown research and biomanufacturing talent in the years ahead to remain internationally competitive.The B.C. governments Life Sciences and Biomanufacturing Strategy takes a thoughtful approach to strengthening the province from the perspective of both economic growth and health preparedness.

Bev Holmes, president and chief executive officer, Michael Smith Health Research BC

The new Life Sciences and Biomanufacturing Strategy further positions British Columbia as a leader in an area that is critical to peoplehere and around the world. The plan aligns with our work to support academic research and maximize benefits of clinical trials, which will create positive impacts on our economy, jobsand health.

Jennifer Figner, interim vice-president, academic and research, British Columbia Institute of Technology (BCIT)

BCITs mandate is to support the workforce development of the province, and we will play a major role in the training needsto ensure the future success and growth of the life sciences sector.With our partner, the Canadian Alliance for Skills and Training in Life Sciences, we look forward to welcominglearners to the National Biomanufacturing Training Centre.

Murray McCutcheon, senior vice-president, partnering, AbCellera

We believe that investments in life sciences talent and infrastructure are critical to building British Columbias ability to translate early scientific innovation into economic growth that makes our communities stronger today and tomorrow.

Suzanne Gill, president and chief executive officer, Genome BC

This new Life Sciences and Biomanufacturing Strategy will supercharge our already world-class life sciences sector and position us as a global leader in research and innovation, delivering new technologies and treatments that benefit B.C., Canadaand the world. Genome BC is proud to support this strategy by championing research and innovation to drive the responsible uptake of genomic technologies.

Cheryl Maitland, interim chief executive officer, Business Council of British Columbia

With an increasing number of scaling companies, highly skilled talent and research advancements, B.C.'s life sciences and biomanufacturing sector is asignificant source of employment, fuelling the growth of clean-tech businesses and contributing to our economy. The newly launched strategypresents a road map to build on these strengths and establish B.C. as a thriving global hubthat positively contributes to British Columbians health and economic well-being.

Deborah Buszard, interim president, University of British Columbia (UBC)

As B.C.s largest health-research and innovation organization and the lead institution for Canadas Immuno-Engineering and Biomanufacturing Hub, UBC welcomes the launch of the B.C. Life Sciences and Biomanufacturing Strategy and looks forward to continued collaboration with partners across academia, health care, industry, non-profits and government.Working together toward the strategys vision, we can create new opportunities for British Columbians and save more lives sooner.

Dr. Penny Ballem,member of the Council of Expert Advisors to the Government of Canada on biomanufacturing and life sciences

The life sciences strategy is an unprecedented opportunity for the remarkable life sciences sector in the province, our academic institutions and the health sector to leverage the investments being made by the federal and provincial government, and work together to benefit the lives of British Columbians and others across the country and globally, and support the biodiversity of our province and the planet.

More:
New strategy positions B.C. as a global hub for life sciences | BC ... - BC Gov News

Unparalleled Research on Advanced Cell Therapies Market With … – Digital Journal

Stratagem Market Insights offers a70% discounton Advanced Cell Therapies Market Reports on Single User Access and Unlimited User Access

The latest research study released by Stratagem Market Insights on Advanced Cell Therapies Market with 100+ pages of analysis on business strategy taken up by emerging industry players, geographical scope, market segments, product landscape and price, and cost structure. It also assists in market segmentation according to the industrys latest and upcoming trends to the bottom-most level, topographical markets, and key advancement from both market and technology-aligned perspectives. Each section of the Advanced Cell Therapies Market business research report is specially prepared to investigate key aspects of the market. This document also entails a detailed analysis of the current applications and comparative analysis with a keen focus on the opportunities and threats and competitive analysis of major companies.

Furthermore, The report provides a detailed understanding of the market segments which have been formed by combining different prospects such as types, applications, and regions. Apart from this, the key driving factors, restraints, potential growth opportunities, and market challenges are also discussed in the report.

Click Here to Get a Sample Copy of the Latest Research on Advanced Cell Therapies Market in 2023 Before Purchase: https://www.stratagemmarketinsights.com/sample/188865

Scope of the Advanced Cell Therapies Market:

The Global Advanced Cell Therapies market is anticipated to rise at a considerable rate during the forecast period, between 2023 and 2030. In 2023, the market is growing at a steady rate and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

The report covers extensive competitive intelligence which includes the following data points:

Competitor Analysis:

The significant players operating in the global Advanced Cell Therapies market are

FRC Blood Service Fujifilm Vericel Advanced Cell Technology Inc Locate Bio Limited Kolon TissueGene Gamida Cell Okyanos Rexgenero BioXcellerator Takura Autolus

The information for each competitor includes:

Company Profiles Company Overview Product Portfolio Financial Performance Recent Developments/Updates Strategies

Market Segmentation

This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides revenue forecast data by type and by application segments based on value for the period 2023-2030.

By Product Type, the market is primarily segmented into:

Stem Cell Transplants CAR T-cell Therapy

By Applications, the market is segmented into:

Stem Cell Regenerative Medicine

Speak to our analyst and gain crucial industry insights that will help your business grow @ https://www.stratagemmarketinsights.com/quiry/188865

Regional Analysis for Advanced Cell Therapies Market:

North America (United States, Canada, and Mexico) Europe (Germany, France, UK, Russia, and Italy) Asia-Pacific (China, Japan, Korea, India, and Southeast Asia) South America (Brazil, Argentina, Colombia, etc.) The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

Covid-19 Impact:

Covid-19 had a major impact on almost all industries. However, several companies operating in the technology sector have seen increased revenue due to significant changes in consumer preferences toward technological services. In addition, the pandemic has led to significant growth in technology across developing and developed countries.

Key Benefits for Stakeholders:

1. The study represents a quantitative analysis of the present Advanced Cell Therapies Market trends, estimations, and dynamics of the market size from 2023 to 2030 to determine the most promising opportunities.2. Porters five forces study emphasizes the importance of buyers and suppliers in assisting stakeholders to make profitable business decisions and expand their supplier-buyer network.3. In-depth analysis, as well as market size and segmentation, help you identify current Advanced Cell Therapies Market opportunities.4. The largest countries in each region are mapped according to their revenue contribution to the market.5. The Advanced Cell Therapies Market research report gives a thorough analysis of the current status of the Advanced Cell Therapies Markets major players.

Reasons To Buy The Advanced Cell Therapies Market Report:

In-depth analysis of the market on the global and regional levels.Major changes in market dynamics and competitive landscape.Segmentation on the basis of type, application, geography, and others.Historical and future market research in terms of size, share growth, volume, and sales.Major changes and assessment in market dynamics and developments.Emerging key segments and regionsKey business strategies by major market players and their key methods.

Buy the Latest Version of the Report Available Now at 70% Discounted Pricing @ https://www.stratagemmarketinsights.com/promobuy/188865

Frequently Asked Questions:

What is the main driving factor for the growth of the global Advanced Cell Therapies market? What are the restraining factors of the market? Who are the key market players? Which region holds the biggest market share? What are the recent trends of the global Advanced Cell Therapies market?

Contact Us:

Stratagem Market Insights

Link:
Unparalleled Research on Advanced Cell Therapies Market With ... - Digital Journal

10 students, alumni win NSF Graduate Research Fellowships – University of Georgia

Two current University of Georgia undergraduate students are among the 10 campus recipients of 2023 National Science Foundation Graduate Research Fellowships.

The NSF Graduate Research Fellowship Program helps ensure the quality, vitality and diversity of the scientific and engineering workforce of the United States. The program recognizes and supports outstanding graduate students who are pursuing full-time research-based masters and doctoral degrees in science, technology, engineering and mathematics (STEM) or in STEM education. The GRFP provides three years of support at $37,000 annually over a five-year fellowship period for the graduate education of individuals who have demonstrated their potential for significant research achievements in STEM or STEM education.

Begun in 1952, this fellowship program is the oldest and most prestigious of its kind; 42 recipients have gone on to become Nobel laureates, and more than 450 have become members of the National Academy of Sciences.

Typically, there are over 12,000 applications for these fellowships annually. This year, there were 2,552 students offered fellowships in all areas of science.

The UGA undergraduate students and alumni winners are:

Andres is a phenomenal student scholar with exceptional promise, said Rachel Roberts-Galbraith, assistant professor in the Franklin College of Arts and Sciences department of cellular biology. In our group, he has made exciting contributions to our goal of understanding how small signaling molecules called neuropeptides promote tissue regeneration and stem cell function. As his mentor, it has been very rewarding to be part of his journey.

Magahey and McSweeney join seven other NSF GRF winners nationally in the category of Geosciences Climate and Large-Scale Atmospheric Dynamics. The undergraduate institutions of the other seven winners were Cornell, Harvard, Princeton and Yale Universities, UC-Berkeley, Rochester Institute of Technology and Worcester Polytechnic Institute. UGA was the only institution with two winners in this category.

Shay and Killian are two of the best students Ive taught in 22 years at UGA, and the best at UGA are as good as the best, anywhere, said John Knox, Josiah Meigs Distinguished Teaching Professor in the Franklin College department of geography. He is also the undergraduate coordinator for the Atmospheric Sciences Program, and a recipient of this fellowship as an undergraduate in 1988. This august company among the top Ivy League schools indicates just how high above the rim the undergraduates in our atmospheric sciences program and geography department are playing.

Magahey and McSweeney have each been involved in research through CURO. McSweeney was first author on a paper based on his undergraduate thesis work published in January in Geophysical Research Letters, a major atmospheric science journal.

Killian and Shay are both self-motivated, independent, and extremely capable researchers. Im thrilled that their achievements and ideas have been recognized with this fellowship award, said Gabriel Kooperman, assistant professor in the department of geography. Ive been so fortunate to have had the opportunity to work with them on research for the last few years and I know they will go on to great success in graduate school.

Five UGA graduate students are also 2023 Fellowship winners:

See the original post:
10 students, alumni win NSF Graduate Research Fellowships - University of Georgia

Flow Cytometry Market Size to Grow USD 104.4 Bn by 2032 … – GlobeNewswire

New York, April 11, 2023 (GLOBE NEWSWIRE) -- Market.us, a leading authority in research, reports that The global flow cytometry market size is expected to be worth around USD 104.4 Billion by 2032 from USD 51.6 Billion in 2022, growing at a CAGR of 7.5% during the forecast period from 2022 to 2032. Flow cytometry is a laser-based technology that is used to analyze the physical characteristic of cells and particles suspended in the fluid by using a laser beam. The method helps to classify cell types to decide the better treatment procedures.

Flow cytometry also detects the residual levels of disease after the treatment. Such factors help with the increasing prevalence of chronic disorders. Also, increasing the adoption of flow cytometry techniques in academics and research and initiatives in the immune-oncology and immunology field is expected to expand the growth of the flow cytometry market. However, the growing adoption of recombinant DNA technology for the production of antibodies offers significant growth opportunities in the global flow cytometry market.

Drivers and challenges have an impact on market dynamics and can impact businesses. Find some insights from a sample report@ https://market.us/report/flow-cytometry-market/request-sample/

Key Takeaway:

Factors affecting the growth of the Flow Cytometry Market?

To understand how our report can bring a difference to your business strategy, Inquire about a brochure athttps://market.us/report/flow-cytometry-market/#inquiry

Top Trends in Global Flow Cytometry Market

In drug discovery and development, the flow cytometry devices method is used for the analysis and detection of physical features of cells, which is emerged as a crucial device for exploratory and safety purposes. The emergence of these devices is due to the quick detection of a large number of cells and the creation of statistically reliable information about the partitions. With the increase in diseases, there is also the growth of clinical trials or research conducted. Clinical trials are conducted to create valuable products for people to reduce the number of infectious diseases, such factors drive the growth of the flow cytometry market.

Market Growth

The increasing adaption of flow cytometry in stem cell research and increasing application of cytometry in clinical trials it is estimated to support the growth of the flow cytometry market across the globe. The increasing incidence of HIV/AIDS, the rising use of flow cytometry technology in research, and the expansion of private and public initiatives for the growth of the flow cytometry market. The increasing rapid advancement in technology, the development of chronic diseases, and the demand for delicate and precise methods support the treatment of diseases.

Regional Analysis

On the basis of geography, the market is segmented into North America, Asia Pacific, Europe, Latin America, and Middle East, and Africa. Due to the presence of healthcare infrastructure and facilities and advanced development North America dominate the flow cytometry market in the world. Also, there is an increase in government focus and investments in technological advancement in flow cytometry devices. Such factors are responsible for the growth of the flow cytometry market in this region. Also, highly estimated research activities by pharmaceutical industries and research institutes help with the increase in demand for the growth of the market in this region. The Asia Pacific region is anticipated to show exponential growth during the projection period. The increase in the development of biotechnology and pharmaceutical companies in India and China.

Planning to lay down future strategy? Request a sample

Scope of the Report

Market Drivers:

The increase in growth of the global flow cytometry market with the growing importance of immune-oncology and immunology research growing acceptance of flow cytometry methods in clinical trials and research activities are the major driving factors for the growth of the flow cytometry market. Also, the flow cytometry meerkat gets support from growing public awareness of academic research and government investments to expand technical improvements.

The pharmaceutical sector shows a significant growth in biotechnology. The latest microfluidic research flow cytometry tools are beneficial devices for examining and handling the micron-sized particles and input of single cells. The major market players focus on their advanced development of flow cytometry devices which will drive the growth of the market during the forecast period.

Market Restraints:

The increase in the number of chronic diseases such as HIV and cancer also increased the use of flow cytometry for diagnostic purposes. But due to a lack of technological advancement and awareness among the prospective end-user, the problems, including the high cost of flow cytometry devices, are estimated to restrict the growth of the flow cytometry market.

Pharmaceutical and biotechnological industries and clinical laboratories require several flow cytometry devices to conduct many research activities, but it requires high cost for the gaining and maintenance of flow cytometry tools. Also, maintenance rates and various indirect expenses raise the total cost of these cytometry devices.

The advanced feature and facilities in the new flow cytometry devices make them more expensive. Due to the high price of flow cytometry devices, there is a decrease in demand for the adoption of flow cytometry devices. Such factors restrict the growth of the flow cytometry market.

Market Opportunities

The adaption of flow cytometry for stem cell research is significantly increasing during the forecast period. The favorable regulatory environment in developing regions and the growing use of stem cells in the treatment of many diseases drive global stem cell research activities. It is supported by the increasing number of financial support and research activities from private and public organizations.

Grow your profit margin with Market.us - Purchase Flow Cytometry Market Report athttps://market.us/purchase-report/?report_id=28460

Report Segmentation of the Flow Cytometry Market

Product Type Insight

Based on the product type, the market is segmented into instruments, software, services, and kits and reagents. The instrument segment is the most dominating segment in the flow cytometry market. Due to advanced technology and higher penetration. The advanced technology with enhanced accuracy, cost-effectiveness, and portability such factors help the growth of the market in the coming years.Due to cost-effectiveness, user-friendly, and allied advantages, the small-sized effective flow cytometers will get high acceptance in the future.

The software also witnesses for getting significant growth in this segment. The software segment is used to control generated data by the cytometers, provide the statistical analysis and analyze the information. The software is used for data analysis and acquisition during clinical diagnosis. A flow cytometer diagnoses the disease by examining the patient's samples. The BD software is specially designed for flow cytometry procedures. This software allows higher-quality experiments in significantly less time, especially for the scientist to monitor oncology, immunology, virology, and infectious diseases.

Technology Insight

Based on technology, the flow cytometry market is segmented into bead-based cytometry and cell-based cytometry. The bead-based flow cytometry is the most dominant technology during the forecast period due to procedural advancement by cell-based technology such as western blot and ElSA. Its ability to detect stability, speed, high reproducibility, and multiple analytes.

The demand for bead-based technology is increased for detecting several infectious diseases using advanced technology due to advancements in molecular engineering, coupled advantages, and cost efficiency, monoclonal antibody production. The bead-based technology is submerged with conjugated antigen molecules to measure antibodies in the fluid. It is used to measure antibody levels in biological fluids. The cell-based technology also shows lucrative growth during the forecast period.

End-User Insight

Based on end users, the market is segmented into Hospitals and Clinics, Academic and Research Institutes, Pharmaceutical, Biotechnology Companies, and Other end users. During the forecast period, the hospitals and clinics segment is the most dominant in the flow cytometry market.

Due to the increase in the prevalence of cancer, HIV, and other infectious diseases in patients, there is an increase in demand for advanced treatment and hospital visits to patients. Also, the presence of good healthcare facilities and infrastructure in hospitals and well-trained doctors in the hospitals such factors help the growth of this segment.

The rise in government policies and advanced development in flow cytometry also helps to drive this segment's growth during the forecast period. The biotechnological and pharmaceutical sectors also show a significant change in the flow cytometry market due to an increase in development activities and advanced research by the biotechnology and pharmaceutical industries. Also, expanding food industries in developing regions such as India and China also help the growth of the flow cytometry market.

To understand how our report can bring a difference to your business strategy, Ask for a brochure@ https://market.us/report/flow-cytometry-market/request-sample/

Market Segmentation

Based on Product Type

Based on Technology

By End-User

By Geography

Competitive Landscape

The competitive landscape of the market has also been examined in this report. Some of the major players include:

Recent Development of the Flow Cytometry Market

June 2022: A brand new cell organizing technology was discovered by Becton, Dickson, and Company at the International Society for the Advancement of Cytometry (ISAC) CYTO 2022. It is a new technology that enables the researcher to analyze a variety of cells at a quick speed is possible now to transform research and development of cell-based therapeutics in various fields, including oncology and virology, and other infectious diseases.

August 2021: Becton, Dickson, and the company discovered the brand-new benchtop cell analyzer known as BD FACSymphony A1 Cell Analyzer. It is expected that labs of all sizes will get benefit from the advanced flow cytometry offered by the fluorescence-activated cell analyst.

Related Reports

About Us:

Market.US(Powered by Prudour Pvt Ltd) specializes in in-depth market research and analysis and has been proving its mettle as a consulting and customized market research company, apart from being a much sought-after syndicatedmarket research report-providing firm. Market.US provides customization to suit any specific or unique requirement and tailor-makes reports as per request. We go beyond boundaries to take analytics, analysis, study, and outlook to newer heights and broader horizons.

Follow Us On LinkedIn Facebook Twitter

Our Blog:

Read the rest here:
Flow Cytometry Market Size to Grow USD 104.4 Bn by 2032 ... - GlobeNewswire

Creative Medical Technology Holdings Inc Witnesses Significant … – Best Stocks

On April 12, 2023, Creative Medical Technology Holdings Inc. (CELZ) witnessed a significant surge in their shares, which rose by over 70%. The reason behind this sudden increase was the announcement made by the company regarding the one-year follow-up data of CELZ-001. This treatment has shown significant efficacy in treating patients with spinal cord injuries. Creative Medical Technology is a renowned biotechnology company that focuses on regenerative medicine, explicitly using adult stem cell treatments to treat immunology, urology, orthopedics, and neurology. The companys patented procedure, StemSpine, treats spinal cord injuries.

The one-year follow-up data of CELZ-001 revealed that it was highly effective in treating patients with spinal cord injuries. The treatment resulted in significant improvements in motor, sensory, and bladder functions. The StemSpine procedure involves using amniotic fluid-derived stem cells for therapeutic applications. The companys core activity is stem cell research and the development of applications for treating male and female sexual dysfunction, infertility, miscarriages, and related issues.

CELZ stock has witnessed high volatility over the past year, with weekly volatility that has increased from 20% to 32%. The company has a market cap of less than $100 million and trades less than 100,000 shares daily. It is important to note that penny stocks are frequently the playground for scam artists.

On April 12, 2023, CELZ stock opened at $0.49 and had a days range of $0.44 to $0.53 with a volume of 140,113 shares traded. The average volume for the past three months was 1,832,378 shares. The market capitalization was unavailable, and the earnings growth for the past year was -112.58%. The revenue growth for the past year was +0.96%. CELZ had no P/E ratio and no price/book ratio data. The price/sales ratio was 47.02. CELZ is a health technology company in the medical specialties industry, with its corporate headquarters located in Phoenix, Arizona. CELZ is expected to report its subsequent earnings on May 31, 2023, with an EPS forecast for this quarter of -$0.10. The annual revenue for the past year was $88.6K, with a yearly profit of -$10.1M. The net profit margin was -11,449.26%.

On April 12, Creative Medical Technology Holdings Inc (CELZ) saw a significant increase in its stock performance. This was because the one analyst offering 12-month price forecasts for the company had a median target of 7.00, with a high estimate of 7.00 and a low estimate of 7.00. This represented a +1,328.57% increase from the last price of 0.49.

Link:
Creative Medical Technology Holdings Inc Witnesses Significant ... - Best Stocks

Flow Cytometry Market Size, Trend Analysis, Opportunities And … – Digital Journal

PRESS RELEASE

Published April 12, 2023

"Flow Cytometry Market Size, Growth by Technology (Cell-based, Bead-based), Product & Service (Analyzer, Sorter, Consumables, Software), Application ((Research - Immunology, Stem cell), (Clinical - Hematology)), End user (Biotech, Hospitals) - Global Forecast to 2027"

Browse 331 market data Tables and 37 Figures spread through 332 Pages and in-depth TOC on "Flow Cytometry Market - Global Forecast to 2027

Flow Cytometry Marketis projected to reachUSD 6.9 billionby 2027, at a CAGR of 8.1%according to a new report by MarketsandMarkets.The growth of the flow cytometry market is largely driven by the rising prevalence of HIV/AIDS and cancer, growing adoption of flow cytometry techniques in research activities, increasing public-private initiatives in immunology and immuno-oncology research, and rising technological advancements in flow cytometry software.

Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=65374584

Browse in-depth TOC on "Flow Cytometry Market"

331 - Tables

37 - Figures

332 Pages

Reagents & consumables segment held major share in flow cytometry market

Based on product & service, the flow cytometry market is segmented into reagents & consumables, instruments, software, services, and accessories. Reagents & consumables accounted for the largest share in the flow cytometry market. The large share of this segment can primarily be attributed to the growing use of flow cytometry techniques in clinical & research applications.

Research application segment dominated the global flow cytometry market

Based on applications, the flow cytometry market is segmented into research, clinical, and industrial applications. The research applications segment accounted for the largest share in the global flow cytometry market. The large share of the research applications segment is mainly due to the growing adoption of flow cytometry in research activities and the increasing availability of flow cytometry services, such as cell sorting, cell cycle analysis, and apoptosis.

North Americahas registered fastest growth rate during the forecast period in flow cytometry market

Geographically, the flow cytometry market is segmented intoNorth America,Europe, theAsia Pacific,Latin America, and theMiddle East&Africa.North Americaaccounted for the largest share in the global flow cytometry market. The large share ofNorth Americain the flow cytometry market is largely driven by the presence of key market players and increasing public-private initiatives for research activities. The market in theAsia Pacificregion is expected to grow at the highest CAGR of 8.6% during the forecast period. The high growth rate of the APAC region can be attributed to the growing pharmaceutical industry; increasing participation of emerging markets in flow cytometry-based research; expansion of research infrastructure; and increasing public-private initiatives to boost advanced proteomics research in the region.

Request Sample Pages:https://www.marketsandmarkets.com/requestsampleNew.asp?id=65374584

Flow Cytometry Market Dynamics:

Drivers:

Restraints:

Opportunities:

Challenges:

Key Market Players:

The prominent players in the flow cytometry market are Becton, Dickinson and Company (US), Danaher Corporation (US), Thermo Fisher Scientific, Inc. (US), Agilent Technologies, Inc. (US), and Luminex Corporation (US). These companies have adopted organic and inorganic growth strategies, such as product launches and acquisitions, to maintain their leading positions in the flow cytometry market.

Recent Developments:

Get 10% Free Customization on this Report:https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=65374584

Media ContactCompany Name: MarketsandMarkets Research Private Ltd.Contact Person: Mr. Aashish MehraEmail: Send EmailPhone: 18886006441Address:630 Dundee Road Suite 430City: NorthbrookState: IL 60062Country: United StatesWebsite: https://www.marketsandmarkets.com/Market-Reports/flow-cytometry-market-65374584.html

See the original post:
Flow Cytometry Market Size, Trend Analysis, Opportunities And ... - Digital Journal

Kenneth C. Griffin makes gift to FAS – Harvard Gazette

The gift also underscores the power of graduate education, with graduate students and faculty creating new knowledge that enhances understanding across every area of study. Those students become the next generation of scholars, with some advancing knowledge and innovation as academic leaders at universities throughout the world and others applying their research to create new therapies, technologies, and tools to advance human health or help drive the economy.

Griffins gift enables such pathways and provides a firm foundation for the FAS to pursue student success and cultivate deep expertise and new collaborations across disciplines and departments.

Harvards Faculty of Arts and Sciences is committed to advancing ideas that will shape humanitys future, while providing important insight into our past, said Griffin. I am excited to support the impactful work of this great institution.

I have witnessed firsthand the impact of Kens philanthropy in my time as Dean of the Faculty of Arts and Sciences, said Claudine Gay, Edgerley Family Dean of the FAS. His extraordinary investment in our institution and, notably, his understanding of the power of unrestricted funds have been essential to our Schools ability to confidently advance academic excellence in service to the world, while navigating headwinds from the pandemic to shifts in the economy.

Griffins gift to the FAS comes at a moment of opportunity as the School undertakes a broad strategic planning process focused on delivering a forward-looking vision for excellence in graduate education, faculty support and development, and organization of academic communities. As part of that broader work in the FAS, the Graduate School convened a faculty-led working group focused on admissions and education, designed to ensure that students graduate with the potential to serve as intellectual leaders for the 21st century.

I am deeply and personally appreciative of the confidence he has placed in us and in our mission to do good in the world.

Larry Bacow, Harvard president

As the Harvard Kenneth C. Griffin Graduate School of Arts and Sciences takes on its new name, it is also marking its 150th anniversary. Situated within the FAS, Harvard Griffin GSAS offers Ph.D. and select masters degrees in over 57 departments and programs. Through degree and non-degree study and visiting and outreach programs, the School connects students with all parts of the University.

As we celebrate our sesquicentennial this year, we are looking ahead to our next 150 years and imagining what our current students will achieve, said Emma Dench, Dean of the Harvard Kenneth C. Griffin Graduate School of Arts and Sciences and McLean Professor of Ancient and Modern History and of the Classics. This investment in the Faculty of the Arts and Sciences cannot help but support our students as they engage in the inquiry and innovation that will ultimately lead to positive impact on the world.

Noting the celebration of the Schools milestone, Bacow reflected on how important graduate education and research are to Harvards mission. Graduate research helped create vaccines to curb the spread of COVID-19, a development made possible by basic research done decades ago that helped scientists understand how mRNA could be used to code proteins that incite a protective immune response, thereby controlling viral infections. Research in philosophy and ethics is now helping guide how colleges and universities educate those who are making advances in artificial intelligence. And research in data science is helping scholars and policymakers understand sources of economic opportunity and social mobility.

Griffins most recent gift builds on his previous support for faculty and students, including the $150 million gift in 2014 to expand undergraduate financial aid.

Last month, Harvard announced another expansion of the Harvard Financial Aid Initiative (HFAI) for low- and middle-income families. Beginning with the class of 2027, the cost to attend Harvard College, which includes tuition, room, board, and all fees, will be free for families with annual incomes below $85,000. This is an increase from the $75,000 annual income threshold announced last year. Today more than half of undergraduate families receive need-based scholarships and one in four families pay nothing toward the cost of a Harvard education.

Griffin, who concentrated in economics and began investing from his dorm room in Cabot House as a sophomore, has also made gifts to the Harvard Graduate School of Education, Harvard Law School, and Harvard Business School. He has supported important University priorities such as stem cell research and, recently, a professorship in economics in honor of Professor Martin Feldstein. In 1999, he established the Wayne R. Gratz Scholarship in honor of his grandfather.

Griffin is the founder and chief executive officer of Citadel, one of the worlds leading alternative investment firms. He is also the founder and non-executive chairman of Citadel Securities, one of the largest market makers in the world. His innovative philanthropic initiatives have made him a leader in advancing breakthroughs in science and medicine, enabling longer and healthier lives, as well as in expanding access and opportunity in education, equipping the next generation of leaders with the tools needed to succeed. Griffins leadership during the COVID-19 crisis helped mobilize partners across government, business, and healthcare to fund critical research and safely rescue hundreds of Americans from Wuhan, China. He also provided crucial thought leadership that laid the foundation for Operation Warp Speed a U.S. program designed to accelerate the creation and distribution of COVID-19 vaccines, therapeutics, and diagnostics.

View original post here:
Kenneth C. Griffin makes gift to FAS - Harvard Gazette

Cord Stem Cell Banking Market to Influence the Value of USD 45.64 Billion by 2030 – openPR

Cord Stem Cell Banking Market

Get Full Report: https://www.databridgemarketresearch.com/reports/global-cord-stem-cell-banking-market

Data Bridge Market Research analyses that the cord stem cell banking market, which was USD 9.3 billion in 2022, would rise up to USD 45.64 billion by 2030 and is expected to undergo a CAGR of 22% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

The cord stem cell banking market is analyzed and market size insights and trends are provided by storage type, product type, service type, source, and indication as referenced above.

The countries covered in the cord stem cell banking market report are U.S., Canada, and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the cord stem cell banking market due to an increase in the presence of major market players in the U.S., ongoing approval of stem cell lines for disease treatment, and growing awareness among the population in this region.

Asia-Pacific is expected to witness significant growth due to a rise in the elderly population, an increase in the incidence of chronic diseases, and growing per capita healthcare expenditure in this region. Also, the developing healthcare infrastructure within the region is boosting market growth.

The cord stem cell banking market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to cord stem cell banking market.

Some of the major players operating in the cord stem cell banking market are:

CBR Systems, Inc., (U.S.) Cordlife (Singapore)Cryo-Cell International, Inc., (U.S.)ViaCord (U.S.)Cryo-Save (Netherlands)LifeCell International Pvt. Ltd. (India)StemCyte India Therapeutics Pvt. Ltd (U.S.)Global Cord Blood Corporation (China)Smart Cells International Limited (U.K.)Vita 34 1997 - 2023, Inc (Germany)Lisata Therapeutics, 2023 (U.S.)BrainStorm Cell Limited (U.S.)Regrow Biosciences Pvt. Ltd. (India)

Browse Other Reports:https://nipapr.blogspot.com/2023/04/hydrastatic-transmission-market-to.html

https://nipapr.blogspot.com/2023/04/label-printing-machines-market-to.html

https://nipapr.blogspot.com/2023/04/video-conferencing-mobile-voip-market.html

https://nipapr.blogspot.com/2023/04/plant-based-spreads-market-to-influence.html

https://nipapr.blogspot.com/2023/04/fine-mist-sprayers-market-to-observe.html

https://nipapr.blogspot.com/2023/04/engine-oil-packaging-market-to.html

Cord Stem Cell Banking Market to Reach USD 45.64 Billion, with an Excellent CAGR of 22% by 2030

https://www.evernote.com/shard/s393/sh/a1782e27-92ff-669e-ead0-5b7d65dbafa4/8Tix9soKMzKr1v0XvZX7ST46yAF6OE-fCcZ985ZxxMjw5BRbbE3XHJ0niQ

https://cynochat.com/read-blog/49118

https://www.gift-me.net/blogs/35424/Cord-Stem-Cell-Banking-Market-to-Reach-USD-45-64

https://diigo.com/0s9c6r

https://www.rolonet.com/blogs/174302/Cord-Stem-Cell-Banking-Market-to-Reach-USD-45-64

https://rentry.org/txpds

https://healthcareprreports.blogspot.com/2023/04/cord-stem-cell-banking-market-to-reach.html

https://www.pickmemo.com/read-blog/142927

https://www.linkedin.com/pulse/cord-stem-cell-banking-market-reach-usd-4564-billion-excellent-gupta

https://pastelink.net/0v0eqj26

https://zenwriting.net/mvmtombzdy

https://justpaste.it/d67c0

https://www.zedlike.com/blogs/74285/Cord-Stem-Cell-Banking-Market-to-Reach-USD-45-64

https://sites.google.com/view/cord-stem-cell-bankingmarket/home

https://legalledger.in/read-blog/16258

https://rollbol.com/blogs/1560937/Cord-Stem-Cell-Banking-Market-to-Reach-USD-45-64

https://demo.sngine.com/blogs/209960/Cord-Stem-Cell-Banking-Market-to-Reach-USD-45-64

https://postheaven.net/f2zlgul0wb

https://poetbook.com/read-blog/150265

https://www.shtfsocial.com/blogs/54807/Cord-Stem-Cell-Banking-Market-to-Reach-USD-45-64

https://writeablog.net/npprngli2m

https://www.campusacada.com/blogs/48578/Cord-Stem-Cell-Banking-Market-to-Reach-USD-45-64

https://kadeum.com/blogs/52069/Cord-Stem-Cell-Banking-Market-to-Reach-USD-45-64

https://cariblime.net/read-blog/48260

Contact Us:-Data Bridge Market ResearchUS: +1 888 387 2818UK: +44 208 089 1725Hong Kong: +852 8192 7475Email:- corporatesales@databridgemarketresearch.com

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

This release was published on openPR.

See more here:
Cord Stem Cell Banking Market to Influence the Value of USD 45.64 Billion by 2030 - openPR